1RT Stock Overview
Operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuformix plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.001 |
| 52 Week Low | UK£0.0005 |
| Beta | 1.22 |
| 11 Month Change | 0% |
| 3 Month Change | -50.00% |
| 1 Year Change | 0% |
| 33 Year Change | -96.77% |
| 5 Year Change | n/a |
| Change since IPO | -98.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1RT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -1.8% |
| 1Y | 0% | -12.8% | 13.6% |
Return vs Industry: 1RT exceeded the German Pharmaceuticals industry which returned -12.8% over the past year.
Return vs Market: 1RT underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 1RT volatility | |
|---|---|
| 1RT Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1RT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1RT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3 | n/a | www.nuformix.com |
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Nuformix plc Fundamentals Summary
| 1RT fundamental statistics | |
|---|---|
| Market cap | €560.27k |
| Earnings (TTM) | -€568.33k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs 1RT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1RT income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£477.89k |
| Earnings | -UK£477.88k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1RT perform over the long term?
See historical performance and comparison